Zum Hauptinhalt springen
Logo Studienallianz LeukämieLogo Studienallianz Leukämie

Rekrutierende Studien

MOSAIC

Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia

PIVOT

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Neoplasia with IDH1 Mutation

SEQUENCE

Sequential gilteritinib in combination with venetoclax and azacitidine for patients with newly diagnosed acute myeloid leukemia (AML) and FLT3 mutations ineligible for intensive treatment.

VINCENT

Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment.